ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

Intravenous rolapitant (Varubi) has received FDA approval for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting in adults, according to TESARO, the manufacturer of the agent.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.